FrancophonIA/ELRC3.0 huggingface dataset:
English: You should tell your doctor if you have any of the following: - low numbers of red or white blood cells - bleeding problems and/or low number of platelets in your blood - diarrhoea, constipation, nausea or vomiting - fainting, dizziness or light-headedness in the past - kidney problems - moderate to severe liver problems - numbness, tingling, or pain in the hands or feet (neuropathy) in the past - heart or blood pressure problems - shortness of breath or cough - seizures - shingles (localised including around the eyes or spread across the body) - symptoms of tumor lysis syndrome such as muscle cramping, muscle weakness, confusion,
Danish: Kontakt lægen, før du bruger bortezomib, hvis du lider af noget af det følgende: - Lavt antal røde eller hvide blodlegemer - Blødningsproblemer og/eller lavt antal blodplader i blodet - Diarré, forstoppelse, kvalme eller opkastning - Tidligere er besvimet, har været svimmel eller ør i hovedet - Problemer med nyrerne - Moderate til svære problemer med leveren - Tidligere har haft problemer med følelsesløshed, følelse af prikken eller smerte i hænder eller fødder (neuropati) - Problemer med hjertet eller blodtrykket - Stakåndethed eller hoste - Krampeanfald - Helvedesild (lokaliseret, også omkring øjnene eller spredt over kroppen) - Symptomer på tumorlysesyndrom, som f.eks. muskelkramper, muskelsvaghed, forvirring,
English: Hazard ratiob (95% CI) p-valuec
Danish: Hazard-ratiob (95 % CI) p-værdic
English: Common Hypertension*, Hypotension*, Orthostatic hypotension
Danish: Almindelig Hypotension*, ortostatisk hypotension, hypertension* Ikke almindelig
English: How to use Bortezomib SUN
Danish: Sådan skal du bruge Bortezomib SUN
English: Very common side effects (may affect more than 1 in 10 people) - sensitivity, numbness, tingling or burning sensation of the skin, or pain in the hands or feet, due to nerve damage - reduction in the number of red blood cells and/or white blood cells (see above) - fever - feeling sick (nausea) or vomiting, loss of appetite - constipation with or without bloating (can be severe) - diarrhoea: if this happens, it is important that you drink more water than usual.
Danish: Meget almindelige bivirkninger (kan forekomme hos flere end 1 ud af 10 patienter) - følsomhed, følelsesløshed, prikken eller en brændende følelse i huden eller smerter i hænder eller fødder pga. nerveskade - reduktion i antallet af røde blodlegemer og/eller hvide blodlegemer (se ovenfor) - feber - kvalme og opkastning, nedsat appetit - forstoppelse med eller uden oppustethed (kan være alvorlig) - diarré.
English: Each 10 ml vial of Bortezomib SUN must be carefully reconstituted with 1.4 ml of sodium chloride 9 mg/ml (0.9%) solution for injection, by using a syringe of the appropriate size, without removing the vial stopper.
Danish: Hvert 10 ml hætteglas med Bortezomib SUN rekonstitueres forsigtigt med 1,4 ml natriumchlorid 9 mg/ml (0,9 %) injektionsvæske ved hjælp af en sprøjte af passende størrelse og uden at fjerne proppen fra hætteglasset.
English: Discontinue bortezomib if PML is diagnosed.
Danish: Hvis PML diagnosticeres, skal bortezomib seponeres.
English: Bortezomib SUN treatment must be initiated under supervision of a physician experienced in the treatment of cancer patients, however Bortezomib SUN may be administered by a healthcare professional experienced in use of chemotherapeutic agents.
Danish: Behandlingen med Bortezomib SUN skal initieres under tilsyn af en læge med erfaring inden for behandling af cancerpatienter.
English: In a drug-drug interaction study assessing the effect of omeprazole, a potent CYP2C19 inhibitor, on the pharmacokinetics of bortezomib (injected intravenously), there was no significant effect on the pharmacokinetics of bortezomib based on data from 17 patients.
Danish: Et lægemiddelinteraktionsstudie til vurdering af effekten af omeprazol, en kraftig CYP2C19-hæmmer, på bortezomibs farmakokinetik (som intravenøs injektion) viste ingen signifikant effekt på bortezomibs farmakokinetik baseret på data fra 17 patienter.
English: If you have not been treated before for multiple myeloma, and you are suitable for blood stem cell transplantation you will receive Bortezomib SUN intravenously or subcutaneously together with the medicines dexamethasone, or dexamethasone and thalidomide, as induction treatment: - When Bortezomib SUN is given together with dexamethasone, you will receive Bortezomib SUN intravenously or subcutaneously as a 21-day treatment cycle.
Danish: Hvis du ikke er blevet behandlet for myelomatose tidligere, og du er egnet til at få transplantation med blodstamceller, vil du få Bortezomib SUN intravenøst eller subkutant samtidig med lægemidlerne dexamethason, eller dexamethason og thalidomid, som induktionsbehandling.
English: The educational material shall consist of the following:
Danish: Regnestokken skal indeholde følgende hovedpunkter:
English: or ANC < 750 cells/μl on a Bortezomib SUN dosing day (other than Day 1 of each cycle)
Danish: ANC-værdien ≤ 0,75 x 109/l på en Bortezomib SUN-dosisdag (bortset fra dag 1)
English: 19.2 mo
Danish: 19,2 mdr.
English: There were 140 patients with ALL or LL enrolled and evaluated for safety; median age was 10 years (range 1 to 26).
Danish: 140 patienter med ALL eller LL blev rekrutteret og evalueret for sikkerhed.
English: Following intravenous bolus administration of a 1.0 mg/m2 and 1.3 mg/m2 dose to 11 patients with multiple myeloma and creatinine clearance values greater than 50 ml/min, the mean first-dose maximum plasma concentrations of bortezomib were 57 and 112 ng/ml, respectively.
Danish: Efter intravenøs bolusindgift af en dosis på 1,0 mg/m2 og 1,3 mg/m2 til 11 patienter med myelomatose og kreatininclearance-værdier på mere end 50 ml/min.
English: Thrombocytopenia*, Febrile neutropenia, Neutropenia*, Leukopenia*, Anaemia*, Lymphopenia* Uncommon Pancytopenia*
Danish: Trombocytopeni*, febril neutropeni, neutropeni*, leukopeni*, anæmi*, lymfopeni*
English: Common Vertigo*
Danish: Almindelig Vertigo* Ikke almindelig
English: Incidence Adverse reaction block*, Cardiovascular disorder (inc cardiogenic shock), Torsade de pointes, Angina unstable, Cardiac valve disorders*, Coronary artery insufficiency, Sinus arrest
Danish: kardiogent shock), torsades de pointes, ustabil angina, hjerteklapsygdomme*, koronarinsufficiens, sinusarrest
English: • different reconstitution requirements for Bortezomib SUN 3.5 mg IV or SC use
Danish: • at kravene til rekonstitution af Bortezomib SUN 3,5 mg er forskellige ved i.v.
English: 1-year Overall Survival (%)e
Danish: Samlet overlevelse efter 1 år (%)e (95 % CI)
English: In Cycles 1-4, Bortezomib SUN is administered twice weekly on days 1, 4, 8, 11, 22, 25, 29 and 32.
Danish: I cyklus 1-4 indgives Bortezomib SUN to gange om ugen på dag 1, 4, 8, 11, 22, 25, 29 og 32.
English: (feeling, hearing, tasting, smelling), attention disturbance, trembling, twitching - arthritis, including inflammation of the joints in the fingers, toes, and the jaw - disorders that affect your lungs, preventing your body from getting enough oxygen.
Danish: spjætten - leddegigt, herunder betændelsestilstand i leddene i fingre, tæer og kæbe - sygdomme, der påvirker lungerne og forhindrer kroppen i at få nok ilt.
English: In a clinical trial, two patients (out of 2) given high-dose cytarabine (2 g/m2 per day) by continuous infusion over 24 hours with daunorubicin and bortezomib for relapsed acute myelogenous leukaemia died of ARDS early in the course of therapy, and the study was terminated.
Danish: Patienterne fik højdosis-cytarabin (2 g/m2 dagligt) ved kontinuerlig infusion over en periode på 24 timer med daunorubicin og bortezomib for recidiverende akut myeloid leukæmi (AML).
English: Rare side effects (may affect up to 1 in 1,000 people) - heart problems to include heart attack, angina - flushing - discoloration of the veins - inflammation of the spinal nerve - problems with your ear, bleeding from your ear - underactivity of your thyroid gland - Budd-Chiari syndrome (the clinical symptoms caused by blockage of the hepatic veins) - changes in or abnormal bowel function - bleeding in the brain - yellow discolouration of eyes and skin (jaundice) - serious allergic reaction (anaphylactic shock) signs of which may include difficulty breathing,
Danish: Sjældne bivirkninger (kan forekomme hos op til 1 ud af 1.000 patienter) - hjerteproblemer, inklusive hjerteanfald, angina pectoris - blussen - misfarvning af blodkarrene - betændelse i rygmarvsnerven - øreproblemer, blødning fra øre - nedsat funktion af skjoldbruskkirtlen - Budd-Cchiaris syndrom (de kliniske symptomer på blokering af levervenerne) - forandringer i eller unormalt afføringsmønster - blødning i hjernen - gulfarvning af øjne og hud (gulsot) - alvorlig allergisk reaktion (anafylaktisk shock).
English: Very common side effects (may affect more than 1 in 10 people) - pneumonia - loss of appetite - sensitivity, numbness, tingling or burning sensation of the skin, or pain in the hands or feet, due to nerve damage - nausea and vomiting - diarrhoea - mouth ulcers - constipation - muscle pain, bone pain - hair loss and abnormal hair texture - tiredness, feeling weak - fever.
Danish: Meget almindelige bivirkninger (kan forekomme hos flere end 1 ud af 10 patienter) - lungebetændelse - appetitløshed - følsomhed, følelsesløshed, prikken eller en brændende følelse i huden eller smerter i hænder eller fødder pga. nerveskade - kvalme og opkastning - diarré - mundsår - forstoppelse - muskelsmerter, knoglesmerter - hårtab og unormal hårstruktur - træthed, svaghed - feber.
English: Hypothyroidism
Danish: Hypotension
English: Combination therapy with melphalan and prednisone Bortezomib SUN is administered via intravenous or subcutaneous injection in combination with oral melphalan and oral prednisone as shown in Table 2.
Danish: Dosering til patienter med tidligere ubehandlet myelomatose, som ikke er egnede til hæmatopoietisk stamcelletransplantation Kombinationsbehandling med melphalan og prednison Bortezomib SUN administreres som intravenøs eller subkutan injektion kombineret med oral melphalan og oral prednison som vist i tabel 2.
English: Each 10 ml vial of Bortezomib SUN must be carefully reconstituted with 3.5 ml of sodium chloride 9 mg/ml (0.9%) solution for injection, by using a syringe of the appropriate size, without removing the vial stopper.
Danish: Hvert 10 ml hætteglas med Bortezomib SUN rekonstitueres forsigtigt med 3,5 ml natriumchlorid 9 mg/ml (0,9 %) injektionsvæske, opløsning ved hjælp af en sprøjte af passende størrelse og uden at fjerne proppen fra hætteglasset.
English: Cerebral haemorrhage*, Haemorrhage intracranial (inc subarachnoid)*, Brain oedema, Transient ischaemic attack, Coma, Autonomic nervous system imbalance, Autonomic neuropathy, Cranial palsy*, Paralysis*, Paresis*, Presyncope, Brain stem syndrome, Cerebrovascular disorder, Nerve root lesion, Psychomotor hyperactivity, Spinal cord compression, Cognitive disorder NOS, Motor dysfunction, Nervous system disorder NOS, Radiculitis, Drooling, Hypotonia
Danish: subaraknoidal-blødning)*, hjerneødem, transitorisk cerebral iskæmi (TCI), koma, forstyrrelser i det autonome nervesystem, autonom neuropati, kraniel parese*, paralyse*, parese*, præsynkope, hjernestammesyndrom, cerebrovaskulær sygdom, nerverodsskade, psykomotorisk hyperaktivitet, kompression af rygmarven, uspecificeret kognitiv forstyrrelse, motorisk dysfunktion, uspecificeret sygdom i nervesystemet, radikulitis, savlen, hypotoni
English: Patients with previously treated light-chain (AL) Amyloidosis An open label non randomised Phase I/II study was conducted to determine the safety and efficacy of bortezomib in patients with previously treated light-chain (AL) Amyloidosis.
Danish: Der blev udført et åbent, ikke-randomiseret fase I/II-studie for at bestemme bortezomibs sikkerhed og virkning hos patienter, der tidligere var blevet behandlet for AL-amyloidose.
English: Corneal lesion*, Exophthalmos, Retinitis, Scotoma, Eye disorder (inc. eyelid) NOS, Dacryoadenitis acquired, Photophobia, Photopsia, Optic neuropathy#, Different degrees of visual impairment (up to blindness)*
Danish: øjenlåg), erhvervet dacryoadenitis, fotofobi, fotopsi, optisk neuropati#, forskellige grader af synsnedsættelse (inkl.
English: Bortezomib SUN in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.
Danish: Bortezomib SUN kombineret med melphalan og prednison er indiceret til behandling af voksne patienter med tidligere ubehandlet myelomatose, som er uegnede til højdosiskemoterapi med hæmatopoietisk stamcelletransplantation.
English: > 1.0 x - 1.5 x ULN Any
Danish: > 1,0-1,5 x ULN Alle
English: Bortezomib is a proteasome inhibitor.
Danish: Virkningsmekanisme Bortezomib er en proteasomhæmmer.
English: chest pain or chest tightness, and/or feeling dizzy/faint, severe itching of the skin or raised lumps on the skin, swelling of the face, lips, tongue and /or throat, which may cause difficulty in swallowing, collapse - movement disorders, paralysis, twitching - vertigo - hearing loss, deafness - disorders that affect your lungs, preventing your body from getting enough oxygen.
Danish: Tegnene på en sådan reaktion kan være vejrtrækningsbesvær, smerter i/trykken for brystet og/eller svimmelhed/følelse af at være ved at besvime, voldsom kløe i huden eller hævede områder på huden, hævelser i ansigt, læber, tunge og/eller svælg, hvilket kan give synkebesvær, kollaps - bevægelsesforstyrrelser, lammelse, spjætten - fornemmelse af at snurre eller dreje rundt - høretab, døvhed - sygdomme, der påvirker lungerne og forhindrer kroppen i at få nok ilt.
English: N=242 (ITT population)
Danish: N=242 (ITTpopulation)
English: When Bortezomib SUN is given in combination with other medicinal products, refer to their Summaries of Product Characteristics for additional contraindications.
Danish: Når Bortezomib SUN gives i kombination med andre lægemidler, bør produktresuméerne for disse lægemidler kontrolleres for yderligere kontraindikationer.
English: Bortezomib combination treatment with pegylated liposomal doxorubicin (study DOXIL-MMY-3001) A Phase III randomised, parallel-group, open-label, multicentre study was conducted in 646 patients comparing the safety and efficacy of bortezomib plus pegylated liposomal doxorubicin versus bortezomib monotherapy in patients with multiple myeloma who had received at least 1 prior therapy and who did not progress while receiving anthracycline-based therapy.
Danish: Der blev udført et randomiseret, parallelgruppe-, åbent, fase III-multicenterstudie med 646 patienter for at sammenligne sikkerheden og effekten af bortezomib plus pegyleret liposomal doxorubicin versus bortezomib som monoterapi hos patienter med myelomatose, som tidligere havde fået mindst 1 behandling, og som ikke progredierede under antracyklin-baseret behandling.
English: - swelling of body, to include eyes and other parts of the body - shivering - redness and pain at injection site - general ill feeling - weight loss - weight increase.
Danish: - hudrødmen - udslæt - muskelspasmer - urinvejsinfektion - smerter i arme og ben - hævelser på kroppen, inklusive øjnene og andre steder på kroppen - kulderystelser - rødmen og smerter på injektionsstedet - generel følelse af at være syg - vægttab - vægtstigning.
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Bortezomib SUN 3.5 mg powder for solution for injection bortezomib
Danish: LÆGEMIDLETS NAVN, STYRKE OG/ELLER ADMINISTRATIONSVEJ(E) Bortezomib SUN 3,5 mg pulver til injektionsvæske, opløsning bortezomib
English: TTP, months
Danish: = måneder.
English: Hepatic reactions
Danish: Leverreaktioner
English: Bortezomib SUN powder has to be dissolved before administration.
Danish: Bortezomib SUN-pulver skal opløses, før det gives.
English: - If you have any further questions, ask your doctor or pharmacist.
Danish: - Spørg lægen, apotekspersonalet eller sundhedspersonalet, hvis der er mere, du vil vide.
English: Bortezomib SUN dose should be reduced by 1 dose level (from 1.3 mg/m2 to 1 mg/m2, or from 1 mg/m2 to 0.7 mg/m2)
Danish: Bortezomib SUN-dosis skal reduceres med 1 dosisniveau (fra 1,3 mg/m2 til 1 mg/m2 eller fra1 mg/m2 til 0,7 mg/m2)
English: There have been reports of PRES in patients receiving bortezomib.
Danish: Posteriort reversibelt encefalopatisk syndrom (PRES) Der er indberettet PRES hos patienter, der fik bortezomib.
English: N=240 (ITT population)
Danish: N=240 (ITTpopulation)
English: Each vial contains 3.5 mg of bortezomib (as a mannitol boronic ester).
Danish: Hvert hætteglas indeholder 3,5 mg bortezomib (som mannitolborsyreester).
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each vial contains 3.5 mg bortezomib (as a mannitol boronic ester).
Danish: ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hvert hætteglas indeholder 3,5 mg bortezomib (som mannitolborsyreester).
English: 1.1 Preparation of the 3.5 mg vial: carefully add 1.4 ml of sterile, 9 mg/ml (0.9%) sodium chloride solution for injection to the vial containing the Bortezomib SUN powder by using a syringe of the appropriate size without removing the vial stopper.
Danish: 1.1 Præparation af 3,5 mg hætteglas: Tilsæt forsigtigt 1,4 ml steril 9 mg/ml (0,9 %) natriumchlorid-injektionsvæske til hætteglasset, der indeholder Bortezomib SUN-pulver ved hjælp af en 1 ml sprøjte og uden at fjerne proppen fra hætteglasset.
English: Testicular disorder*, Prostatitis, Breast disorder female, Epididymal tenderness, Epididymitis, Pelvic pain, Vulval ulceration
Danish: Vaginalblødning, genitale smerter*, erektil dysfunktion Sjælden Testikelsygdom*, prostatitis, sygdom i mammae hos kvinder, epididymal ømhed, epididymitis, bækkensmerter, sårdannelse på vulva
English: # Post-marketing adverse reaction regardless of indication
Danish: * Indikerer termer, der omfatter mere end én MedDRA ”foretrukken term” # Indberetninger efter markedsføring, uanset indikation
English: Bortezomib SUN in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.
Danish: Bortezomib SUN kombineret med dexamethason eller med dexamethason og thalidomid er indiceret til behandling af voksne patienter med tidligere ubehandlet myelomatose, som er egnede til højdosiskemoterapi med hæmatopoietisk stamcelletransplantation.
English: Anaphylactic shock, Amyloidosis, Type III immune complex mediated reaction
Danish: Angioødem#, overfølsomhed* Sjælden Anafylaktisk shock, amyloidose, immunkompleksmedieret (type III-) overfølsomhedsreaktion
English: After reconstitution, 1 ml of solution for intravenous injection contains 1 mg bortezomib.
Danish: Efter rekonstitutionen indeholder 1 ml injektionsvæske, opløsning til intravenøs injektion 1 mg bortezomib.
English: In Cycles 5-9, Bortezomib SUN is administered once weekly on days 1, 8, 22 and 29.
Danish: I cyklus 5-9 indgives Bortezomib SUN en gang om ugen på dag 1, 8, 22 og 29.
English: (95% CI) Hazard ratio (95% CI)c p-valued
Danish: Hazard-ratio (95 % CI) c p-værdid
English: 1.1 Preparation of the 3.5 mg vial: carefully add 3.5 ml of sterile, 9 mg/ml (0.9%) sodium chloride solution for injection to the vial containing the Bortezomib SUN powder by using a syringe of the appropriate size without removing the vial stopper.
Danish: 1.1 Præparation af 3,5 mg hætteglas: Tilsæt forsigtigt 3,5 ml steril 9 mg/ml (0,9 %) natriumchlorid-injektionsvæske til hætteglasset, der indeholder Bortezomib SUN-pulver ved hjælp af en 1 ml sprøjte og uden at fjerne proppen fra hætteglasset.
English: 4.2 mo
Danish: 4,2 mdr.
English: NAME OF THE MEDICINAL PRODUCT Bortezomib SUN 3.5 mg powder for solution for injection
Danish: LÆGEMIDLETS NAVN Bortezomib SUN 3,5 mg pulver til injektionsvæske, opløsning
English: Hair disorder*
Danish: Almindelig Synsforstyrrelser*
English: Nausea and vomiting symptoms*, Diarrhoea*, Constipation
Danish: Kvalme og opkastning*, diarré*, obstipation
English: Prednisone is given orally at 100 mg/m2 on days 1, 2, 3, 4 and 5 of the Bortezomib SUN treatment cycle.
Danish: Prednison gives oralt 100 mg/m2 på dag 1, 2, 3, 4 og 5 i behandlingscyklussen med Bortezomib SUN.
English: Common Sepsis (inc septic shock)*, Herpes zoster (inc disseminated & ophthalmic), Herpes virus infection*, Bacterial infections*, Upper/lower respiratory tract infection*, Fungal infection*, Herpes simplex* Uncommon Hepatitis B, Infection*, Bronchopneumonia
Danish: dissemineret og oftalmisk), herpesvirusinfektion*, bakterieinfektion*, øvre/nedre luftvejsinfektion*, svampeinfektion*, herpes simplex*
English: Bortezomib exposure is increased in patients with moderate or severe hepatic impairment; these patients should be treated with bortezomib at reduced doses and closely monitored for toxicities (see sections 4.2 and 5.2).
Danish: Disse patienter skal behandles med reducerede doser bortezomib og overvåges nøje for bivirkninger (se pkt.
English: Common Oedema (inc peripheral), Chills, Pain*, Malaise* Uncommon General physical health deterioration*, Face oedema*, Injection site reaction*, Mucosal disorder*, Chest pain, Gait disturbance, Feeling cold, Extravasation*, Catheter related complication*, Change in thirst*, Chest discomfort, Feeling of body temperature change*, Injection site pain*
Danish: Almen fysisk helbredsforringelse*, ansigtsødem*, reaktion på injektionsstedet*, slimhindegener*, smerter i brystet, gangforstyrrelser, kuldefornemmelse, ekstravasation*, kateterrelaterede komplikationer*, forandringer i væskebehov*, trykken for brystet, fornemmelse af ændret legemstemperatur*, smerter på injektionsstedet*
English: After reconstitution, 1 ml of solution for subcutaneous injection contains 2.5 mg bortezomib.
Danish: Efter rekonstitutionen indeholder 1 ml injektionsvæske, opløsning til subkutan injektion 2,5 mg bortezomib.
English: chest pain or chest tightness, and/or feeling dizzy/faint, severe itching of the skin or raised lumps on the skin, swelling of the face, lips, tongue and /or throat, which may cause difficulty in swallowing, collapse - breast disorders - vaginal tears - genital swelling - inability to tolerate alcohol consumption - wasting, or loss of body mass - increased appetite - fistula - joint effusion - cysts in the lining of joints (synovial cysts) - fracture - breakdown of muscle fibers leading to other complications - swelling of the liver, bleeding from the liver - cancer of the kidney - psoriasis like skin condition - cancer of the skin - paleness of the skin - increase of platelets or plasma cells (a type of white cell) in the blood - blood clot in small blood vessels (thrombotic microangiopathy) - abnormal reaction to blood transfusions - partial or total loss of vision - decreased sex drive - drooling - bulging eyes - sensitivity to light - rapid breathing - rectal pain - gallstones - hernia - injuries - brittle or weak nails - abnormal protein deposits in your vital organs - coma - intestinal ulcers - multi-organ failure - death.
Danish: Tegnene på en sådan reaktion kan være vejrtrækningsbesvær, smerter i/trykken for brystet og/eller svimmelhed/omtumlethed, voldsom kløe i huden eller hævede områder på huden, hævelser i ansigt, læber, tunge og/eller svælg, der kan give synkebesvær, kollaps - sygdom i brysterne - vaginale rifter - hævelse af kønsorganerne - kan ikke tåle at drikke alkohol - hensygnen eller tab af kropsmasse - øget appetit - fistler - ledeffusion - cyster i ledkapslerne (synoviale cyster) - brud på knogle eller brusk - henfald af muskelfibre med følgetilstande - hævelse af leveren, blødning fra leveren - nyrekræft - psoriasislignende hudsygdom - hudkræft - bleg hud - øget antal blodplader eller plasmaceller (en type hvide celler) i blodet - blodprop i små blodkar (trombotisk mikroangiopati) - unormal reaktion på blodtransfusioner - delvist eller totalt synstab - nedsat sexlyst - savlen - udstående øjne - følsomhed over for lys - hurtig vejrtrækning - smerter i endetarmen - galdesten - brok - skader - skrøbelige eller svage negle - unormal aflejring af protein i vigtige organer - koma